Richard Lane/Robert Holden Methadone Advocacy Award

Richard Lane was a long-term heroin user who, upon release from prison in 1967 helped to start Man Alive, one of the Nation’s first methadone treatment programs. In 1974, he became Executive Director of the program and later served as Vice President of the American Methadone Treatment Association. He served on several committees and was Vice Chairman of the Governor’s Council on Alcohol and Drug Abuse in Maryland. Richard was a passionate advocate for methadone treatment and, by disclosing his own treatment experiences, provided inspiration to patients and professionals alike.

He did more for advancing methadone treatment because he genuinely knew the subject and really, really cared about the underdog. Among the innovations he promoted within the methadone program were on-site alcoholism treatment, protocols for poly-drug abuse, services for patients with acquired immune deficiency syndrome, improved pain management for methadone patients, and fewer restrictions for socially rehabilitated patients on methadone including office based treatment which he did not enroll in himself. After a long and courageous battle with cancer, Richard Lane died in 1994.

Robert Holden was also a recovering heroin user and a friend of Richard Lane. He eventually became the Director of PIDARC, an outpatient methadone treatment program in the District Of Columbia. And he also served as the Vice President of the American Association for the Treatment of Opioid Dependence, succeeding Richard Lane’s term of office.

Robert was a different kind of advocate, he was not dynamic like Richard Lane. Robert was quieter but when needed he could speak about how methadone had saved his life and like Richard Robert used his own experience to get the point across. Robert Holden died in 2007 of Bone Marrow Cancer.

The award is presented at the AATOD Conference during the Awards Banquet by NAMA Recovery for AATOD. This award was established in 1995 and recognizes extraordinary achievements in patient advocacy.

Previous Awardees

1995 Richard Lane

2001 Joycelyn Woods

2007 Anthony Scro

2009 Walter Ginter

2010 Lisa Mojer-Torres

Instructions for Nominations

Deadline

The nominee and all the requested information must be submitted by Monday, August 22, 2011.

Criteria

  1. Only one (1) nominee can be submitted to the Conference Awards Committee. There may be a number of nominees, who will be fielded by NAMA Recovery in the medication assisted treatment MAT (i.e. methadone and/or buprenorphine) patient advocacy movement, however, NAMA Recovery will be responsible for submitting only one (1) “consensus” nominee to receive this honor.
  2. The nominee must have been involved in the field of methadone and/or buprenorphine advocacy for a period of five (5) years.
  3. The nominee must have been actively engaged in methadone and/or buprenorphine advocacy for a period of five (5) years.
  4. The nominee must have made meaningful and consistent contributions, which have had a significant impact on opioid treatment within a state or region of the United States.

Information to Submit

For each Nominee the NAMA Recovery Selection Committee must receive a “Completed Nomination Form”. A blank Nomination Form can be downloaded from this page.

At least 2 Letters of Support must accompany the Nomination Form. (you can submit more than 2)

The Letters of Support should detail the accomplishments and contributions made by the Nominee.

Where to Submit the Nominee Information

The Nomination Form and Letters of Support should be submitted to Joycelyn Woods at 

Suggestions for Persons Nominating an Advocate

  1. Start by contacting the person you want to nominate and tell them of your intentions. (not everyone may want to be nominated for an award)
  2. Ask them for their CV or Resume and use this to complete the Nomination Form.
  3. Ask the proposed awardee to suggest 2 persons to write Letters of Support.
  4. Send a copy of the Nomination Criteria to each person that will write a Letter of Support.
  5. Remind the 2 writers of the letters of support to send you the letters before the deadline.
  6. Send the completed Nomination Form to the proposed awardee and ask them to review it to make sure you have everything listed.
  7. Submit the Nomination Form and 2 Letters of Support by August 22, 2011.

If you have any questions contact: 

Download

Nomination Form

Criteria

Press Release

Return to Home Page

Similar Posts

  • Author: NAMA Recovery-1

    Admin 07/01/2022

    Nominations Open for the 2022 Richard Lane/Robert Holden Advocacy Award! May 1, 2022 Richard Lane was a long-term heroin user who, upon release from prison in 1967, was instrumental in establishing one of the Nation’s first opioid treatment programs. In 1974, he became the Executive Director of Man Alive and later served as Vice President…

  • |

    Buprenorphine Information for Physicians

    Admin 05/07/2023

    Federal Law Basic Information About DATA On October 17, 2000 Title XXXV of the Children’s Health Act of 2000 was enacted that permits the prescribing of schedule III, IV or V opioid treatment drugs that are approved by the FDA for maintenance or detoxification treatment. Read the full text: Public Law 106-310, Sec. 3502. Controlled…

  • |

    DRAFT

    Admin 06/23/2022

    Model Policy Guidelines for Opioid Addiction Treatment in the Medical Office Draft approved for distribution July 2001 THE FEDERATION OF STATE MEDICAL BOARDS OF THE UNITED STATES, INC. Introduction On October 17, 2000, “The Children’s Health Act of 2000” (HR 4365) was signed into federal law. Section 3502 of that Act sets forth the “Drug…

  • Publication Index

    Admin 03/18/2022

    FOR IMMEDIATE RELEASE: October 9, 2002 NIDA Contact: Michelle Person 301-443-6245 SAMHSA Contact: Leah Young 301-443-8956 NIDA Research and SAMHSA Physician Training Combine to Put Care for Opiate Dependence in Hands of Family Doctor. Buprenorphine, a new medication developed through more than a decade of research supported by the National Institute on Drug Abuse (NIDA),…

  • New Methadone Regulations in the U.S.

    Admin 05/07/2021

    Press Release July 22, 1999 National Alliance of Methadone Advocates NAMA 435 Second Avenue New York, NY 10010 Email: [email protected] NAMA applauds the hard work of SAMHSA, the ONDCP, NIDA and CSAT for the release of the New Accreditation Guidelines for Methadone and LAAM Treatment. We are aware that these agencies have made tremendous efforts…

  • TENNESSEE & Northwest Georgia NAMA-R

    Admin 12/21/2021

    Tennessee/NW Georgia Chapter of the National Alliance for Medication Assisted Recovery   And we believe in the 5 goals of NAMA-R: To eliminate discrimination toward methadone patients. To create a more positive image about methadone maintenance treatment. To help preserve patient’s dignity and their rights. To make treatment available on demand to every person who…